Related Experiment Video

Updated: May 9, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Polymorphism of angiotensinogen gene M235T in myocardial infarction and brain infarction: a meta-analysis

Xinyue Liang1, Jie Qiu, Xiangju Liu

  • 1Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, People's Republic of China.

Gene
|August 13, 2013
PubMed

Insights

The angiotensinogen (AGT) M235T gene polymorphism is linked to increased risk of myocardial infarction (MI) and brain infarction (BI) specifically in East Asian populations. This meta-analysis clarifies previous inconclusive findings for this genetic association.

Area of Science:

  • Genetics
  • Cardiovascular disease
  • Neurology

Background:

  • The angiotensinogen (AGT) gene M235T polymorphism has been inconsistently associated with myocardial infarction (MI) and brain infarction (BI).
  • Previous studies on the AGT M235T polymorphism and its link to cardiovascular and cerebrovascular events have yielded conflicting results.
  • Clarifying the association between the AGT M235T polymorphism and the risk of MI and BI is crucial for understanding genetic predispositions.

Purpose of the Study:

  • To conduct a meta-analysis to resolve controversies regarding the association between the angiotensinogen (AGT) gene M235T polymorphism and the risk of myocardial infarction (MI) and brain infarction (BI).
  • To systematically evaluate existing studies to determine the conclusive relationship between AGT M235T polymorphism and these cardiovascular and cerebrovascular events.

Main Methods:

  • A systematic literature search of electronic databases was performed up to February 2013.
  • Included 38 studies comprising a total of 17,304 participants.
  • Meta-analysis was employed to synthesize data and assess the association using various genetic models (dominant, recessive, additive).

Main Results:

  • A significant association was observed between the AGT M235T polymorphism and the risk of MI and BI in the East Asian population across dominant, recessive, and additive models.
  • The M235T polymorphism did not show a significant impact on the risk of MI in the total population or in other ethnic groups.
  • Subgroup analyses by gender and age did not provide sufficient evidence to support an association.

Conclusions:

  • The meta-analysis suggests a significant association between the angiotensinogen (AGT) M235T polymorphism and an increased risk of myocardial infarction (MI) and brain infarction (BI) specifically within the East Asian population.
  • The AGT M235T polymorphism is a potential genetic risk factor for MI and BI in East Asians.
  • Further large-scale international studies are recommended to elucidate the genetic basis of MI and BI and confirm these findings across diverse populations.
Keywords:
AGTAngiotensinogenBIBrain infarctionCIGene polymorphismHWEHardy–Weinberg equilibriumMIMeta-analysisMyocardial infarctionORRAASangiotensinogenbrain infarctionconfidence intervalmyocardial infarctionodds ratiorenin–angiotensin–aldosterone system

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...